Radiopharma

Jubilant Radiopharma is an industry-leading pharmaceutical company specializing in nuclear medicine. The company is focused on developing, manufacturing, commercializing and distributing high quality, sustainable diagnostic and therapeutic agents for the sole purpose of IMPROVING LIVES THROUGH NUCLEAR MEDICINE on a global scale.

Nearly a thousand strong and growing, the business consists of two distinct divisions; The Radiopharmaceuticals Division and the Radiopharmacies Division.

Radiopharmaceuticals

Radiopharmaceuticals Division has a solid foundation in developing, manufacturing and commercializing radiopharmaceuticals used for the diagnosis and treatment of various diseases.

Headquartered in Montreal, Canada this division has over 60-years of experience serving the global Nuclear Medicine community and the patients they serve.

The Radiopharmaceuticals Division employs over 170 highly skilled employees and is dedicated to providing high-quality radiopharmaceuticals and cutting-edge technologies to its customers. Backed by a global network of R&D facilities and staff, we are positioning ourselves to be the global leader in Nuclear Medicine by making significant investments in early- and late-stage product development.

The Division has strong partnerships and ongoing collaborations with the National Institute of Health (NIH), medical societies, regulatory agencies, and key opinion leaders across the globe in pursuit of its vision to Improve Lives Through Nuclear Medicine.

The U.S. Food and Drug Administration (FDA), Health Canada, International Organization for Standardization (ISO), Canadian Nuclear Safety Commission (CNSC) and Nuclear Regulatory Commission (NRC) regulate and certify the company’s highly specialized manufacturing facility from a pharmaceutical, radioactive and device perspective.

We offer a broad portfolio of products which include diagnostic and therapeutic agents, as well as state-of-the-art devices, for cardiology, oncology, pulmonology, and endocrinology.

Our products are supplied to national commercial radiopharmacy networks, regional health systems, stand-alone imaging centers, and hospitals worldwide. The bedrock of the business are its lyophilized “cold kits”, radioactive “hot products” and more recently a cutting edge cardiac PET tracer (Rb-82).

The Division continues to increase the range of product offerings in North America, while expanding into the Latin America, European and Asian markets through collaboration, contractual arrangements with partners and new distribution channels to drive growth in current and future products.
Our Radiopharmacies procures and supply only FDA inspected and accredited radiopharmaceutical products from cGMP compliant manufacturers and fully support USP compounding standards during compounding and dispensing. Additionally, in accordance with the State Boards of Pharmacy regulations, prescription orders are required for all radiopharmaceutical products dispensed.

We offer a wide spectrum of nuclear medicine products and services that provide safe and cost-effective ways to image the body and treat diseases. Our radiopharmacies are open formulary, providing our customers with a full array of radiopharmaceutical product options. This allows clinicians to select the products they prefer to achieve the highest benefit for their patients. We deliver what they need, where they need it, when they need it.

The Division through its “Institute of Learning” is dedicated to advancing the field of Nuclear Medicine through education and sharing of innovative best practices. Through the Institute, the team creates a community of subject matter experts available to consult on clinical, technical, and regulatory matters.
PRODUCT OFFERINGS
Jubilant DraxImage Distribution Countries
(Approved & Marketed Products – Current Listing as on September 1, 2018)

USA
Drax Exametazime™
DRAXIMAGE® MAA
DRAXIMAGE® DTPA
DRAXIMAGE® I-131 Diagnostic Capsules
HICON® Sodium Iodine I 131 Solution USP
DRAXIMAGE® MDP-25
DRAXIMAGE® Sestamibi
SMART-FILL® Dispensing System
RUBY-FILL® (Rubidium Rb82 Generator & RUBY Rubidium Elution System)

CANADA
RUBY-FILL® (Rubidium Rb82 Generator)
RUBY Rubidium Elution System Device
DRAXIMAGE® MDP-25
DRAXIMAGE® MAA
DRAXIMAGE® DTPA
DRAXIMAGE® I-131 Diagnostic Capsules
DRAXIMAGE® I-131 Diagnostic Solution
DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® I-131 Therapeutic Solution
DRAXIMAGE® MDP-10
DRAXIMAGE® Sestamibi
DRAXIMAGE® Gluceptate
HICON® Sodium Iodine I 131 Solution USP

EUROPE
United Kingdom
DRAXIMAGE® Sestamibi (DRAXMIBI)
DRAXIMAGE® MDP-10

ROW
Columbia
DRAXIMAGE® Sestamibi (pending)
DRAXIMAGE® MDP-10

Bermuda
DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® DTPA
DRAXIMAGE® MAA

Barbados
DRAXIMAGE® DTPA

Jamaica
DRAXIMAGE® DTPA
DRAXIMAGE® Sestamibi
DRAXIMAGE® Gluceptate
DRAXIMAGE® MDP-10
DRAXIMAGE® I-131 Therapeutic Solution

Trinidad & Tobago
DRAXIMAGE® I-131 Therapeutic Solution
DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® MDP-10

Netherlands
DRAXIMAGE® MDP-10
DRAXIMAGE® Sestamibi

Switzerland
RUBY-FILL® (Rubidium Rb82 Generator)

Luxembourg
RUBY-FILL® (Rubidium Rb82 Generator)

Germany
RUBY-FILL® (Rubidium Rb82 Generator)
<table>
<thead>
<tr>
<th>Country</th>
<th>Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venezuela</td>
<td>HICON® Sodium Iodine I 131 Solution USP</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>DRAVMAGE® I-131 Diagnostic Solution</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® MAA</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>DRAVMAGE® I-131 Therapeutic Solution</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® I-131 Therapeutic Capsule</td>
</tr>
<tr>
<td>New Zealand</td>
<td>DRAVMAGE® MDP-10</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® MAA</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® DTPA</td>
</tr>
<tr>
<td>Israel</td>
<td>DRAVMAGE® MDP-10</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® MAA</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® DTPA</td>
</tr>
<tr>
<td>Philippines</td>
<td>DRAVMAGE® MDP-10</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® MAA</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® DTPA</td>
</tr>
<tr>
<td>KSA</td>
<td>DRAVMAGE® MDP-10</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® DTPA</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® Sestamibi</td>
</tr>
<tr>
<td></td>
<td>DRAVMAGE® Gluceptate</td>
</tr>
<tr>
<td>India</td>
<td>DRAVMAGE® Sestamibi</td>
</tr>
</tbody>
</table>

**State of the Art Facility**

- 3 Hot Cells
- 1 Isolator
- 1 Automated Loading Station
- 4 Semi-Automated Loading Stations
- Packaging Station

**Regulatory and Quality Approvals:**

- ISO 13485:2016
- ISO CE Mark Certified
- Health Canada
- US-FDA (Inspected/Accredited)
- CNSC (Canadian Nuclear Safety Commission)
- NRC (US Nuclear Regulatory Commission)
# Product Portfolio For Your Diagnostic & Therapeutic Needs

<table>
<thead>
<tr>
<th>Brain Imaging</th>
<th>Cardiac PET Imaging</th>
<th>Kidney Imaging</th>
<th>Bone Imaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>• DTPA and Gluceptate</td>
<td>• RUBY-FILL®</td>
<td>• DTPA and Gluceptate</td>
<td>• MDP</td>
</tr>
<tr>
<td>Thyroid Therapy</td>
<td>Cardiac SPECT Imaging</td>
<td>Functional Lung Imaging</td>
<td>Leukocyte Labeling</td>
</tr>
<tr>
<td>• I-131 Iodine and HICON®</td>
<td>• Sestamibi</td>
<td>• MAA and DTPA</td>
<td>• Exametazime</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Jubilant DraxImage, Inc.**  
16751, Trans-Canada Highway,  
Kirkland (Montreal), Québec, Canada H9H 4J4  
Tel : 1-800-361-2356 or +514-694-8220  
Our offices are open Monday to Friday from 8:00 AM to 5:00 PM Eastern Time  
For business inquiries e-mail: customerservice@jdi.jubl.com  
www.draximage.com